Buy or sell Metacrine stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Request Access

View More Companies

Metacrine Stock

Metacrine is a privately held biotech company

Founded

2015

Notable Investors

ARCH Venture Partners

Headquarters

San Diego CA, US

Total Funding

$123M

About Metacrine Stock

Metacrine is a privately held biotech company  founded in 2015 on technology licensed from the  laboratory of Dr. Ronald Evans, a world leader in  nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. Metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

Investors

ARCH Venture Partners

Grail, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics

Franklin Templeton Investments

Lacework, Snyk, SpotOn, Checkr, Gong.io, 6sense, Sweetgreen, Talkdesk, Lime, Rent the Runway

Funding History

August 2015	$36.0M
December 2017	$22.0M
June 2018	$65.0M

Management

CEO

Neil McDonnell

CFO

Trisha Millican

CEO & President

Ken Song

Press

Metacrine Completes Dosing of First Cohort in Phase 1 Trial of MET409, a Novel Non-Bile Acid FXR Agonist

GlobeNewswire (press release) - Jun, 13 2018

Metacrine Completes $65M Series C Financing

FinSMEs (blog) - Jun, 8 2018

Metacrine to Present at 30th Annual ROTH Conference and HC Wainwright & Co. 2nd Annual NASH Investor Conference

PR Newswire (press release) - Mar, 7 2018

Metacrine raises $22M to advance liver drug for humans

The San Diego Union-Tribune - Dec, 7 2017

Other Companies

Learn More

BlueWillow Biologics

BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company.

CellMax Life is a biotechnology company that is focused on developments in early cancer detection and prevention.

CeraPedics is a medical device company that focuses on developing and commercializing novel osteobiologic products.

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.

Route 92 Medical is a medical device company developing a catheter to treat stroke.

7Age (years)

$140MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 280K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Request Access

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2022 EquityZen Inc. All rights reserved.